NYSE Euronext accueille DBV Technologies sur son marché européen


Fourth French life sciences company to list in one month

Paris, 29 March 2012 – DBV Technologies, creator of Viaskin®, a new product used in the treatment of allergies, today celebrated its admission to trading on NYSE Euronext in Paris.

Founded in 2002, DBV Technologies developed and patented an innovative therapeutic solution that combats some of the most severe allergies in adults and children, including peanuts, milk proteins and mites. Its unique and revolutionary approach is based on a patch called Viaskin® that desensitizes allergy sufferers. This uses a new non-invasive delivery system to deliver active compounds to the skin epidermis without breaking the blood-skin barrier, thus dramatically reducing secondary effects. The company currently has 27 employees and plans to sell Viaskin® in Europe and the United States in response to rising demand from patients and physicians. 

DBV Technologies (ticker code: DBV) was admitted to NYSE Euronext by direct listing of the 8,822,745 shares making up its capital, and the issue of 4,573,171 new shares as part of a Global Offering[1] including full exercise of the extension clause. The total amount raised under the global offering was €49 million.

The admission and issue price of DBV Technologies shares was set at €10.82 each. The company’s capitalisation came to around €160 million on the day of admission.

We are delighted to welcome DBV Technologies to NYSE Euronext in Paris. Coming after medical technology experts EOS imaging and Intrasense, and biotech specialists Adocia, this is the fourth very successful listing on our European market of a French life sciences company in a month,” said Marc Lefèvre, Head of European Coverage at NYSE Euronext. “All four listings also highlight investment funds’ ongoing contribution to promoting innovative SMEs and the role funds play alongside the stock market in providing financing for businesses.

Pierre-Henri Benhamou, Chairman & CEO and co-founder of DBV Technologies, said: “A stock-market listing for DBV Technologies is the logical conclusion of our development and full-scale production of Viaskin®. I’m very pleased that our listing has been such a success, since the proceeds will enable us to continue financing clinical studies now under way and take advantage of all of the potential that our Viaskin® patch offers. Our innovative patch technology can dramatically change the quality of everyday life for millions of people, and our positioning in this area, combined with a development strategy targeting allergists, gives our company scope for major growth and the strategic assets we need to become a leader in allergy treatments. We estimate sales potential for Viaskin® in its first three applications at over $5 billion. I want to extend my heartfelt thanks to all our teams and to everyone who has contributed to the success of our listing, along with the shareholders who backed us earlier and those who have now joined us and will be sharing in our future growth.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.